Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immunomodulatory Effects of Histone Deacetylation Inhibitors in Graft-vs.-Host Disease After Allogeneic Stem Cell Transplantation.

Literature DB >> 33732262

Immunomodulatory Effects of Histone Deacetylation Inhibitors in Graft-vs.-Host Disease After Allogeneic Stem Cell Transplantation.

Xiaoxiao Xu^1,2,3,4, Xiaoqin Li^1,2,3,4, Yanmin Zhao^1,2,3,4, He Huang^1,2,3,4.

Abstract

Histone deacetylase inhibitors are currently the most studied drugs because of their beneficial effects on inflammatory response. Emerging data from numerous basic studies and clinical trials have shown that histone deacetylase inhibitors can suppress immune-mediated diseases, such as graft-vs.-host disease (GVHD), while retaining beneficial graft-vs.-leukemia (GVL) effects. These drugs prevent and/or treat GVHD by modifying gene expression and inhibiting the production of proinflammatory cytokines, regulating the function of alloreactive T cells, and upregulating the function and number of regulatory T cells. Some of these drugs may become new immunotherapies for GVHD and other immune diseases.

Entities: Chemical Disease Gene Species

Keywords: allo-reactive T cells; allogeneic hematopoietic stem cell transplantation; epigenetic regulation; graft-vs.-host disease; histone deacetylase inhibitors

Year: 2021 PMID： 33732262 PMCID： PMC7959724 DOI： 10.3389/fimmu.2021.641910

Source DB: PubMed Journal: Front Immunol ISSN： 1664-3224 Impact factor: 7.561

53 in total

1. AS1387392, a novel immunosuppressive cyclic tetrapeptide compound with inhibitory activity against mammalian histone deacetylase.

Authors: Satoshi Sasamura; Kazutoshi Sakamoto; Shoji Takagaki; Toshiko Yamada; Shigehiro Takase; Hiroaki Mori; Takashi Fujii; Motohiro Hino; Michizane Hashimoto
Journal: J Antibiot (Tokyo) Date: 2010-06-30 Impact factor: 2.649

Review 2. Epigenetic therapy of cancer: past, present and future.

Authors: Christine B Yoo; Peter A Jones
Journal: Nat Rev Drug Discov Date: 2006-01 Impact factor: 84.694

3. Valproic Acid Ameliorates Graft-versus-Host Disease by Downregulating Th1 and Th17 Cells.

Authors: Jun Long; Li Chang; Yan Shen; Wen-Hui Gao; Yue-Nv Wu; Han-Bo Dou; Meng-Meng Huang; Ying Wang; Wei-Yue Fang; Jie-Hui Shan; Yue-Ying Wang; Jiang Zhu; Zhu Chen; Jiong Hu
Journal: J Immunol Date: 2015-07-15 Impact factor: 5.422

Review 4. Current and emerging strategies for the prevention of graft-versus-host disease.

Authors: Sung Won Choi; Pavan Reddy
Journal: Nat Rev Clin Oncol Date: 2014-06-24 Impact factor: 66.675

5. A novel SCFA receptor, the microbiota, and blood pressure regulation.

Authors: Jennifer Pluznick
Journal: Gut Microbes Date: 2013-12-20

Review 6. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma.

Authors: Karen M VanderMolen; William McCulloch; Cedric J Pearce; Nicholas H Oberlies
Journal: J Antibiot (Tokyo) Date: 2011-05-18 Impact factor: 2.649

7. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents.

Authors: H-S Lin; C-Y Hu; H-Y Chan; Y-Y Liew; H-P Huang; L Lepescheux; E Bastianelli; R Baron; G Rawadi; P Clément-Lacroix
Journal: Br J Pharmacol Date: 2007-02-26 Impact factor: 8.739

8. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease.

Authors: Tangsheng Yi; Ying Chen; Lin Wang; Gong Du; Daniel Huang; Dongchang Zhao; Heather Johnston; James Young; Ivan Todorov; Dale T Umetsu; Lieping Chen; Yoichiro Iwakura; Fouad Kandeel; Stephen Forman; Defu Zeng
Journal: Blood Date: 2009-07-14 Impact factor: 22.113

9. Control of cytokine mRNA degradation by the histone deacetylase inhibitor ITF2357 in rheumatoid arthritis fibroblast-like synoviocytes: beyond transcriptional regulation.

Authors: Chiara Angiolilli; Pawel A Kabala; Aleksander M Grabiec; Marzia Rossato; Wi S Lai; Gianluca Fossati; Paolo Mascagni; Christian Steinkühler; Perry J Blackshear; Kris A Reedquist; Dominique L Baeten; Timothy R D J Radstake
Journal: Arthritis Res Ther Date: 2018-07-20 Impact factor: 5.156

Immunomodulatory Effects of Histone Deacetylation Inhibitors in Graft-vs.-Host Disease After Allogeneic Stem Cell Transplantation.

1. AS1387392, a novel immunosuppressive cyclic tetrapeptide compound with inhibitory activity against mammalian histone deacetylase.

Review 2. Epigenetic therapy of cancer: past, present and future.

3. Valproic Acid Ameliorates Graft-versus-Host Disease by Downregulating Th1 and Th17 Cells.

Review 4. Current and emerging strategies for the prevention of graft-versus-host disease.

5. A novel SCFA receptor, the microbiota, and blood pressure regulation.

Review 6. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma.

7. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents.

8. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease.

9. Control of cytokine mRNA degradation by the histone deacetylase inhibitor ITF2357 in rheumatoid arthritis fibroblast-like synoviocytes: beyond transcriptional regulation.

10. Entinostat augments NK cell functions via epigenetic upregulation of IFIT1-STING-STAT4 pathway.

Review 1. The Pathophysiology and Treatment of Graft-Versus-Host Disease: Lessons Learnt From Animal Models.

Review 2. An Overview of Autophagy in Hematopoietic Stem Cell Transplantation.

Review 3. Translational Clinical Strategies for the Prevention of Gastrointestinal Tract Graft Versus Host Disease.

Review 4. Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy.

Review 5. T Helper Cell Lineage-Defining Transcription Factors: Potent Targets for Specific GVHD Therapy?